Amicus Therapeutics Reaches Profitability Milestone in Q3 2025

The biotechnology firm Amicus Therapeutics has achieved a significant financial breakthrough, reporting its first GAAP profit in years during the third quarter of 2025. This specialist in rare disease treatments reached profitability amid substantial revenue expansion, potentially signaling a sustained upward trajectory for its shares.

Robust Revenue Growth Across Product Portfolio

Amicus Therapeutics demonstrated impressive commercial performance across its key therapeutic offerings. Total revenue climbed 17% to $169.1 million, driven by strong results from both established and newer treatments.

The company’s flagship product Galafold recorded a 15% increase in sales, while the Pompe disease therapy combination of Pombiliti + Opfolda saw remarkable growth, surging 45% during the quarter. This balanced performance across the product portfolio underscores the company’s commercial execution capabilities.

Financial Performance Exceeds Expectations

The company’s transition to profitability marked a pivotal moment in its corporate development. Amicus reported a GAAP net income of $17.3 million, achieving profitability under generally accepted accounting principles. Even more notably, non-GAAP earnings reached $0.18 per share, surpassing analyst projections by an impressive 50%.

This profitability milestone represents a crucial validation of the company’s business model and growth strategy, coming after years of investment in research and commercial infrastructure.

Should investors sell immediately? Or is it worth buying Amicus Therapeutics?

Development Pipeline and Global Expansion

Beyond its current commercial success, Amicus is advancing its next phase of growth through clinical development and international expansion. The Phase 3 trial for DMX-200, targeting the rare kidney disease FSGS, continues according to schedule. Patient recruitment is expected to conclude by year-end, representing a critical milestone for a therapeutic area that currently lacks approved treatments.

The company is simultaneously executing on its global strategy, with recent regulatory approvals secured in Japan and Belgium. Amicus plans to launch its products in up to ten additional countries before the close of the year. These developments bring the company’s long-term target of exceeding $1 billion in annual revenue by 2028 within closer reach.

Analyst Community Responds Positively

Financial analysts have taken note of Amicus Therapeutics’ improved performance. J.P. Morgan raised its price target to $19 while maintaining an “Overweight” rating on the shares. Goldman Sachs followed with an increase from $9 to $11, though it maintained a “Neutral” stance on the company.

The consensus price target among covering analysts stands at approximately $30, suggesting substantial potential upside from the current trading level around €8. The company will have its next opportunity to make its case to investors at the Jefferies Global Healthcare Conference in London on November 18.